MannKind Corp.
www.mannkindcorp.com
Latest From MannKind Corp.
Glenmark Readies New Diabetes Combo In India
Glenmark is working on a combination of remogliflozin and teneligliptin in India, which if successful could bring additional sting to its portfolio in the country's bustling diabetes segment. But Boehringer-Lilly’s rival Glyxambi already has a head-start.
10 Drug Launch Flops Of The Decade
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.
Deal Watch: Pfizer Licenses Skin-Targeted JAK Inhibitor Portfolio From Theravance
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.
US FDA Advertising Citations Remain Rare In 2018
With only seven letters last year, Office of Prescription Drug Promotion appears to be continuing its enforcement retrenchment as agency reconsiders its approach to Rx communications.
Company Information
- Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
- Therapeutic Areas
- Cardiovascular
- Gastrointestinal
- Metabolic Disorders
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- MannKind Corp.
- Senior Management
-
Michael Castagna, CEO
Steven Binder, CFO
David M Kendall, MD, CMO
Patrick McCauley, Chief Commercial Officer - Contact Info
-
MannKind Corp.
Phone: (818) 661-5000
30930 Russell Ranch Rd., Ste. 301
Westlake Village, CA 91362
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice